Elekta stock
EKTA-B.STSTOElekta AB (publ), HealthcareISIN SE0000163628
56Score 56 out of 100, Neutral
Price and trend
84 / 100
Price history
+37% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 2.7% below its 52-week high. Largest decline in 20 years: 70% (November 2019 to November 2025).
Chart figures for advanced users
- SMA 50$5.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.44
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.25
- The lowest closing price of the last twelve months.
- Resistance$6.34
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Elekta AB (publ) belongs to the Medical (Devices) industry (Sweden) and, with a market value of $2.27B, is number 39 of 88 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.68B (down 7.2% year on year) and a loss of $52.14M.
- For fiscal 2027, analysts expect on average revenue of $1.74B (up 3.7%) and adjusted earnings per share of $0.40 (up 68.7%).
Show more
- MEQIRI Score 56 out of 100 (Neutral): rank 319 of 702 in Healthcare, median 53.
- Our model puts fair value at $11.30, with the price 45% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 45% below the fair value of $11.30.Valuation 85
- Reliable dividendNo dividend cut for 12 years.
- High dividend yieldDividend yield 3.9%, Medical (Devices) median 1.66%.
Weaknesses
- Margin fallingOperating margin 2.6%, average of the prior years 11.3% (to 2025).Profitability 26
- Interest barely coveredOperating profit covers interest only 1.2 times.Stability 41
- Loss-makingLoss of $36.3M over the last 12 months.
Its standout strengths are valuation and technical analysis, while growth and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- calm price action
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $8.07 and expensive above $18.84 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 7.4%. At 8.4% the fair value would be $9.37, at 6.4% it would be $14.15.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Jul 2026, revenue fell 6.9% on the twelve months before. Revenue has grown solidly since 2007, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 37%, operating 3%, net −3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Nov 2026in 12 days
- Last reported
- 27 Aug 2026EPS reported $0.07 (expected $0.05)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.40+0.2%
- Revenue
- $1.74B+0.6%
- Earnings per share
- $0.44+0.1%
- Revenue
- $1.81B+0.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.6%Guidance reiterated: revenue growth of 2% to 4% at fixed currency, with positive growth expected in Q2.
“And for '26-'27, we continue to expect net sales growth of 2% to 4% in constant currency and an adjusted EBIT margin of 12.5% to 13.5%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Aug 2026 (fiscal Q1 2027), read by AI.
What happened at Elekta
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 56
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- GN Store NordGN.CO $2.63B55
- NeogenNEOG $2.44B41
- UFP TechnologiesUFPT $2.37B76
- Drägerwerk AG & Co. KGaADRW3.DE $2.31B66
- Establishment Labs HoldingsESTA $2.05B41
- Butterfly NetworkBFLY $1.78B45
- Embla Medical hf.EMBLA.CO $1.76B67
- ChemoMetecCHEMM.CO $1.76B78
ETFs that hold Elekta
Held by 17 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G ROBO Global Robotics and Automation UCITS ETFIROB | 1.32% | 0.80% | €1.58B |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.50% | 0.38% | €86.74M |
| iShares OMX Stockholm Capped UCITS ETFOM3X | 0.25% | 0.10% | €198.93M |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 0.23% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.20% | 0.40% | €813.42M |
| WisdomTree Europe Equity Income UCITS ETFWTEE | 0.18% | 0.29% | €241.09M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.13% | 0.30% | €3.45B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.12% | 0.30% | €813.64M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Apr 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.